EUVIMEDEUVIMED entdecken
Crossref

Population modeling analyses of crizotinib in pediatric patients with ALK‐positive advanced cancers

Li Jerry iD, Lin Swan, Nickens Dana, Frank M Balis, Emily Greengard iD, Xu Huiping

Pediatric Blood & Cancer · 2024

DOI: 10.1002/pbc.31139 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pediatric Blood & Cancer, 2024. Verfasst von Li Jerry und 5 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacology, Pfizer Inc., New York, New York, USA. Hauptthemen laut MEDLINE: Crizotinib, Anaplastic Lymphoma Kinase, Protein Kinase Inhibitors. Die Arbeit nennt 9 Literaturangaben. Gefördert von: Pfizer Inc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Alterations in the ALK (anaplastic lymphoma kinase) gene play a critical role in pathogenesis of anaplastic large cell lymphoma (ALCL). Crizotinib is a small molecule competitive inhibitor of ALK, ROS1, and MET kinases and was approved for pediatric patients with ALK‐positive relapsed or refractory, systemic ALCL, and ALK‐positive unresectable, recurrent, or refractory inflammatory myofibroblastic tumors (IMT). Procedure Crizotinib data from pediatric patients with relapsed or refractory solid tumors, IMT, or ALCL were included in the analyses. All patients received crizotinib orally at doses ranging from 100 to 365 mg/m 2 twice daily (BID). PopPK analyses were conducted to characterize crizotinib disposition in pediatric patients. Exposure–response (ER) safety and antitumor analyses were conducted to characterize relationships between crizotinib dose or exposure with safety and antitumor activity endpoints of interest.

Results

The population pharmacokinetic (popPK), ER safety, and ER antitumor analysis included 98, 110, and 36 pediatric patients, respectively. A one‐compartment pharmacokinetic model with allometric scaling, first‐order elimination, and first‐order absorption with lag time adequately described the data. Natural log‐transformed model‐predicted crizotinib AUC ss (steady‐state area under the concentration–time curve) demonstrated a significant, positive relationship with Grade ≥3 NEUTROPENIA and Any Grade VISION DISORDER. Crizotinib dose demonstrated a positive relationship with objective response rate.

Conclusions

No significant differences in PK were identified across a wide range of ages or across tumor types, suggesting body surface area (BSA)‐based dosing adequately adjusted for differences in patient size to achieve similar systemic crizotinib exposures across young children and adolescent pediatric patients. None of the myelosuppressive events except Grade ≥3 NEUTROPENIA had significant relationships identified with crizotinib dose or exposure, suggesting crizotinib is a tolerable treatment with less hematological toxicity than traditional chemotherapy regimens for pediatric patients with ALK‐mutated cancers. Results from the presented analyses support the pediatric dosing recommendations in the product label.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CrizotinibAnaplastic Lymphoma KinaseProtein Kinase InhibitorsHumansChildFemaleMaleAdolescentChild, PreschoolNeoplasmsLymphoma, Large-Cell, AnaplasticYoung AdultInfant

Stichwörter der Autor:innen

ALCLIMTcrizotinibefficacypharmacokineticssafety

Substanzen

CrizotinibAnaplastic Lymphoma KinaseALK protein, humanProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Clinical Pharmacology, Pfizer Inc., New York, New York, USA.
  • Clinical Pharmacology, Neurocrine Biosciences, San Diego, California, USA.
  • Department of Pediatrics, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
  • Department of Pediatrics, University of Minnesota, Minneapolis, Minnesota, USA.

ORCID-Profile: Li Jerry, Emily Greengard

Förderung

  • Pfizer Inc

Zitieren

APA

Jerry, L., Swan, L., Dana, N., Balis, F. M., Greengard, E., & Huiping, X. (2024). Population modeling analyses of crizotinib in pediatric patients with ALK‐positive advanced cancers. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.31139

Vancouver

Jerry L, Swan L, Dana N, Balis FM, Greengard E, Huiping X. Population modeling analyses of crizotinib in pediatric patients with ALK‐positive advanced cancers. Pediatric Blood & Cancer. 2024. doi:10.1002/pbc.31139

BibTeX
@article{Jerry2024,
  author = {Jerry, Li and Swan, Lin and Dana, Nickens and Balis, Frank M and Greengard, Emily and Huiping, Xu},
  title = {Population modeling analyses of crizotinib in pediatric patients with ALK‐positive advanced cancers},
  journal = {Pediatric Blood & Cancer},
  year = {2024},
  doi = {10.1002/pbc.31139}
}
Kostenlos starten →